← Back to signals
INBX
Inhibrx Biosciences, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
10.0d↓-1.3%
as of 2026-10-30 · shares short vs 2026-09-30
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | −78K | 9.3% | +1.5% vs SPY -0.7% abs | 2026-08-14 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | -16.2% vs SPY -10.7% abs | 2026-05-15 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (2)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Viking Global | Andreas Halvorsen | 1.1M | $111M |
| Point72 | Steve Cohen | 17K | $2M |
Quarter-end 13F positions for the tracked funds holding this stock.